To include your compound in the COVID-19 Resource Center, submit it here.

Copaxone glatiramer acetate: Completed Phase III enrollment

Teva completed enrollment of about 1,400 patients in the double-blind, international Phase III

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE